Human growth hormone (UK).

CURRENT TOPIC Biosynthetic human growth hormone treatment in the UK : an audit of current practice

Biosynthetic human growth hormone was licensed for use in the UK in 1985, shortly after the withdrawal of human pituitary derived growth hormone because of the risk of Creutzfelt-Jakob disease.1 The primary indication remains the treatment of short stature due to growth hormone deficiency; the short stature of Turner's syndrome was a later approved indication. The release of biosynthetic growth...

An ln vivo Assay for Biological Activity of Synthesized Recombinant Human Growth Hormone

Evaluation of Heat Induction Strategy for Recombinant Human Growth Hormone Expression in Fed-Batch Fermentation

Using L-arabinose for Production of Human Growth Hormone in Escherichia coli, Studying the Processing of gIII::hGH Precursor

CONSTRUCTION OF RECOMBINANT PLASMIDS FOR PERIPLASMIC EXPRESSION OF HUMAN GROWTH HORMONE IN ESCHERICHIA COLI UNDER T7 AND LAC PROMOTERS

In order to study the periplasmic expression of human growth hormone (hGH) in Escherichia coli, the related cDNA was inserted in two expression plasmids carrying pelB signal peptide, one with lac bacterial promoter and the other with a bacteriophage T7-based promoter. The recombinant plasmids were moved to TG1 and BL21 strains of E. coli, respectively. To induce the expression systems, IPTG and...

CYTOKINE AND GROWTH FACTOR MODULATION OF CELL CYCLE EVENTS IN HUMAN MELANOMA CELL LINES

Cytokines influence cell cycle events, which in some but not all instances can be associated with melanoma progression. Analysis of the G0/G 1 and S phase fractions of the cell cycle was used to assay the proliferative or inhibitory activity of cytokines against ten human melanoma cell lines, including pairs of cell lines derived from primary and metastatic tissue of individual patients. Cy...